Bauer L A, Brown T, Gibaldi M, Hudson L, Nelson S, Raisys V, Shea J P
Clin Pharmacol Ther. 1982 Apr;31(4):433-7. doi: 10.1038/clpt.1982.56.
Lidocaine kinetics were examined during continuous infusions in five healthy subjects using stable isotope lidocaine labeled with two deuterium atoms. During phase 1, lidocaine and stable isotope lidocaine (50 mg IV each) were given as a bolus to confirm that the two species were kinetically identical. Phase 2 consisted of a long-term (30 hr) lidocaine infusion designed to produce a steady-state concentration equal to 1.5 microgram/ml. Twenty-four hours into the infusion, stable isotope lidocaine (50 mg) was given as an intravenous bolus and kinetic parameters were calculated. Phase 3 differed from phase 2 in that target steady-state lidocaine concentration was 4 microgram/ml and the stable isotope lidocaine dose was reduced to 40 mg. A gas chromatograph-mass spectrometer was used to determine lidocaine and stable isotope lidocaine serum concentrations. Compared to phase 1, clearance decreased (P less than 0.05) and half-life increased (P less than 0.025) during phases 2 and 3. The volume of distribution at steady-state remained constant during all three phases. Lidocaine cumulated in serum during long-term infusions in all five patients; repeated decreases in infusion rate were necessary to avoid exceeding desired target concentrations in phases 2 and 3.
使用标记有两个氘原子的稳定同位素利多卡因,对五名健康受试者在持续输注过程中的利多卡因动力学进行了研究。在第1阶段,将利多卡因和稳定同位素利多卡因(各50毫克静脉注射)作为推注给药,以确认这两种物质在动力学上是相同的。第2阶段包括一次长期(30小时)的利多卡因输注,旨在产生等于1.5微克/毫升的稳态浓度。输注24小时后,静脉推注稳定同位素利多卡因(50毫克)并计算动力学参数。第3阶段与第2阶段的不同之处在于,目标稳态利多卡因浓度为4微克/毫升,稳定同位素利多卡因剂量降至40毫克。使用气相色谱 - 质谱仪测定利多卡因和稳定同位素利多卡因的血清浓度。与第1阶段相比,在第2阶段和第3阶段清除率降低(P<0.05),半衰期延长(P<0.025)。在所有三个阶段中,稳态分布容积保持恒定。在所有五名患者的长期输注过程中,利多卡因在血清中累积;在第2阶段和第3阶段,需要反复降低输注速率以避免超过期望的目标浓度。